FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 4 filers reported holding FATE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $424,000 | -55.6% | 200,000 | 0.0% | 0.14% | -46.3% |
| Q2 2023 | $956,000 | -16.1% | 200,000 | 0.0% | 0.27% | -13.8% |
| Q1 2023 | $1,140,000 | +98.2% | 200,000 | +250.9% | 0.31% | +110.1% |
| Q4 2022 | $575,130 | -55.0% | 57,000 | 0.0% | 0.15% | -57.8% |
| Q3 2022 | $1,277,000 | -9.6% | 57,000 | 0.0% | 0.35% | +5.7% |
| Q2 2022 | $1,412,000 | -36.1% | 57,000 | 0.0% | 0.33% | -26.5% |
| Q1 2022 | $2,209,000 | -33.8% | 57,000 | 0.0% | 0.45% | -32.2% |
| Q4 2021 | $3,335,000 | -1.3% | 57,000 | 0.0% | 0.67% | -7.1% |
| Q3 2021 | $3,378,000 | -37.2% | 57,000 | -8.1% | 0.72% | -30.1% |
| Q2 2021 | $5,380,000 | +0.4% | 62,000 | -4.6% | 1.03% | +2.3% |
| Q1 2021 | $5,359,000 | -21.4% | 65,000 | -13.3% | 1.00% | -23.6% |
| Q4 2020 | $6,819,000 | +70.6% | 75,000 | -25.0% | 1.31% | +58.7% |
| Q3 2020 | $3,997,000 | +16.5% | 100,000 | 0.0% | 0.83% | +11.0% |
| Q2 2020 | $3,431,000 | +209.1% | 100,000 | +100.0% | 0.75% | +191.4% |
| Q1 2020 | $1,110,000 | +13.5% | 50,000 | 0.0% | 0.26% | +34.0% |
| Q4 2019 | $978,000 | – | 50,000 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |